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Abstract
Background: Different molecular therapies like the EGFR-inhibiting antibody cetuximab have
come into clinical practice. Cetuximab is EMEA-approved for metastatic colorectal cancer and
advanced squamous-cell head and neck cancer. Administration is said to be safe and well tolerated
with common, usually mild dermatologic side effects.
Case presentation: We present the case of a patient with fatal complications after
oesophagectomy and neoadjuvant chemotherapy including cetuximab for squamous-cell
esophageal cancer. A transthoracic en-bloc oesophagectomy was performed. Few days later the
patient died due to gas exchange dysfunction and circulation instability after a previously unseen
combination of drain-erosion of the stomach with subsequent pleurisy and air leak of the left main
bronchus.
Conclusion: So far we have never observed this fatal combination of drain erosion of the stomach
with fibrinous pleurisy and unmanageable progressive tracheal defect before. The role of cetuximab
in the multifactorial aetiology of damages of stomach and trachea after oesophagectomy remains
unclear since we are not able to link the complication directly to cetuximab or definitely exclude
it as a sole surgical complication. Clinicians should be aware of the possibility of fatal side effects
and careful recording of all complications is necessary in ongoing and planned studies to obtain
more evidence about safety and tolerance of targeted therapies.
Background
Oesophageal cancer represents the sixth leading cause of
cancer-related death in the world. Despite recent advances
in surgical critical care medicine and combined modality
therapies 5-year overall survival rates (10–14%) are unsat-
isfactorily low [1]. The only curative therapy in localized
cancer is provided by radical surgery. However, more than
50% of all patients are diagnosed with inoperable or met-
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astatic disease [2]. Next to radical surgery compared with
chemoradiotherapy alone [3], neoadjuvant chemother-
apy approaches have been studied with a pathologic com-
plete response rate (pCR) of up to 24% [4]. Although
some authors state that still no standard recommendation
can be given for a multimodality therapy outside clinical
trials [5], randomised trials exist showing survival benefits
after neoadjuvant chemotherapy and therefore neoadju-
vant chemotherapy is considered part of standard practice
in many institutions[6].
In the last decade different molecular therapies have
changed the field of research, trying to inhibit or modu-
late targets of signal transduction pathways. One of those
that made it into clinical practice is the epidermal growth-
factor receptor (EGFR) inhibiting chimeric antibody
cetuximab (Erbitux, Merck Pharma Gmbh, Darmstadt,
D). This monoclonal antibody blocks EGF and TGF-α
binding to the extracellular domain of EGFR, which
results in cell-growth inhibition, induction of apoptosis
and decreased production of EGF [7].
Cetuximab is EMEA-approved for second line treatment
of EGFR-expressing metastatic colorectal cancer refractory
to irinotecan-based chemotherapy and locally advanced
squamous-cell head and neck cancer with concomitant
radiotherapy. Many solid tumors including esophageal
cancer overexpress EGFR, predicting poor survival, poor
response to therapy as well as higher probability for dis-
ease progression and resistance to therapy [8-10]. This
makes cetuximab a promising anticancer agent for differ-
ent neoplasms, but so far no clinical trials have been
reported in esophageal cancer patients. Ongoing trials
include two studies in metastatic esophageal cancer
(South-west Oncology Group trial and Memorial Sloan-
Kettering Cancer Center study) and one preoperative
phase II trial with cisplatin, irinotecan, cetuximab and
radiation at Dana-Farber Cancer Institute [11].
Generally EGFR-antibodies (e.g. cetuximab, matuzumab,
panitumumab) or EGFR tyrosine kinase inhibitors (e.g.
gefitinib, erlotinib) are said to be safe and well tolerated
without systemic side-effects of chemotherapy. Common
dermatologic side effects of cetuximab in a considerable
number of patients are acneiform eruptions, xerosis,
eczema, fissures, teleangiectasia, hyperpigmentation, hair
changes and paronychia [12]. More severe adverse reac-
tions are grade 3 to 4 allergic reactions and severe dysp-
nea.
In this report we present a case report with fatal postoper-
ative complications after neoadjuvant chemotherapy
including cetuximab for squamous-cell esophageal cancer
and discussion of the literature.
Case presentation
A 52-year old man was diagnosed with squamous-cell
esophageal cancer of the lower third. Pretherapeutical
investigations included endoscopical biopsy, CT scan,
endosonography and mediastinoscopy with lymph-node
biopsy. These investigations showed a locally advanced
stage T4N1 cancer.
The patient was scheduled for two cycles of neoadjuvant
radiochemotherapy with cisplatin 100 mg per m2 and 5-
FU 1000 mg per m2. After the first chemotherapy cycle the
patient developed grade 3 mucositis and esophagitis com-
bined with an infection of the port-a-cath system, which
had to be removed. This intense toxicity gave us reason to
search for a dihydropyrimidin-dehydrogenase-deficiency.
The result of the genetic testing was negative. Because of
the toxic esophagitis and mucositis the patient refused to
undergo the planned radiotherapy. From the second cycle
continous 5-FU was replaced by oral capecitabine because
of the port-a-cath infection and cetuximab was added as
an alternative to radiotherapy after informed consent in a
compassionate use setting. The EGFR-testing had shown a
strong overexpression in all tumor cells. The treatment
consisted of an intravenous standard loading dose of 400
mg per m2 after administration of diphenhydramine and
ranitidine and continued with 250 mg per m2 once weekly
for four weeks. After five weeks the patient developed dis-
seminated pustules with generalized deeply infiltrated
erythematous plaques highly indicative for a severe acute
generalized exanthematic pustulosis (AGEP) as shown in
figure 1. These symptoms diminished after four days of
dexamethasone, cefuroxime, silver sulfadiazine cream
and diphenhydramine therapy. Because of this severe
adverse effect cetuximab was stopped and a restaging CT
scan was performed.
Reevaluation showed nearly no remission of the tumor as
well as stable disease in the suspect lymph nodes. Because
of lack of response and the intense toxicity the patient
wanted to stop the neoadjuvant therapy and proceeded to
transthoracic en bloc oesophagectomy five weeks after the
last cetuximab application. Replacement of the esophagus
was performed with an orthotopic gastric tube and cervi-
cal esophago-gastrostomy. On the third postoperative day
a leakage from the right thoracic drain was observed and
the following immediate revision operation showed an
erosion of the stomach, which was most likely caused by
a thoracic drain positioned in the vicinity of the gastric
tube. The anastomosis 3 cm above the defect was com-
pletely intact with macroscopic sufficient blood circula-
tion. Because of an additional fibrinous pleurisy we had to
conduct a disconnection esophagostomy, catheter-gas-
trostomy and -jejunostomy for early enteral feeding. After
four days the patient developed an airleak of the left main
bronchus just below the tracheal bifurcation. At the timeWorld Journal of Surgical Oncology 2007, 5:114 http://www.wjso.com/content/5/1/114
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of the first bronchoscopy we found a 5 mm ulcer where
the tracheal tube cuff was located during the operation
until extubation on the first postoperative day. Within
four days the defect's size increased by fourfold as shown
in figure 2 and a tracheal stent had to be implanted. This
stent successfully closed the leak for several hours until a
second leakage above the first was observed which was
covered by the cuff of the tracheal tube. Neither the stent
nor the cuff could successfully reduce the airleak and the
situation demanded a right-sided intubation. Three days
later the patient died due to refractory gas exchange dys-
function and circulation instability.
Surgical treatment after neoadjuvant therapy
The patient's squamous-cell esophageal cancer of the
lower third (35 – 38 cm from incisor teeth) was treated by
en bloc transthoracic oesophagectomy with paraesopha-
geal, paratracheal, aorto-pulmonary and paracardial lym-
phadenectomy including lymph nodes of the splenic,
hepatic and celiac arteries followed by cervical esoph-
agogastrostomy under general anesthesia with separate
intubation. The operation time was 4.5 hours and the
blood loss approximately 600 ml. The reoperation con-
sisted of a disconnection esophagostomy, catheter-gas-
trostomy and -jejunostomy. The tracheal leakage was
treated by a 12 French Dumont silicone stent.
Tumor
Histologic tumor studies were done by haematology and
eosin staining and EGFR-overexpression was measured by
EGFR Pharm Dx kit K 1494 (Dako Cytomation).
Surgical specimen
The oesophageal tumour was staged as ypT3 N1(9/25)
MX R0 on final pathology. After reoperation the histologic
examination of the resected specimen revealed extensive
ischemic necrosis of the gastric mucosa with erosions and
microabscesses, oedematous submucosa and the muscu-
lar and serosal layer next to the defect in good order.
Autopsy
The autopsy showed massive fibrinous pleurisy, medias-
tinitis, left-sided bronchitis and bronchopneumonia in
addition to the 2 cm tracheal defect of the membranous
part of the left main bronchus. Histological complete tra-
cheal wall destruction was observed with fibrin, necrotic
areas and focal formation of granulation tissue without
evidence of residual tumour (figure 3).
Discussion
So far we have never observed this fatal combination of
drain erosion of the stomach with fibrinous pleurisy and
unmanageable progressive tracheal defect. Tracheal fistu-
lae with airleaks are rare but life threatening complica-
tions after esophageal resections one to thirty days after
oesophagectomy. The reported incidence of tracheal
lesions is about 4 percent and about a third of the patients
dies during the postoperative course, mostly because of
unhealed lesions at the bifurcation or in the left main
stem bronchus [13]. Ischemia after peritracheal dissection
was the pathologic explanation in about half of the cases.
Preoperative radiochemotherapy predisposed to this com-
plication significantly and also in our patient neoadjuvant
chemotherapy including cetuximab was administered. In
Severe acute generalized exanthematic pustulosis (AGEP)  five weeks after first cycle of cetuximab therapy Figure 1
Severe acute generalized exanthematic pustulosis (AGEP) 
five weeks after first cycle of cetuximab therapy.
Unmanageable increase of tracheal damage within four days Figure 2
Unmanageable increase of tracheal damage within four days. 
Left picture with a small 0.5 cm defect, in center defect 
increasing after 2 days and the rightmost picture shows a 2 
cm defect of the left main bronchus short before death of the 
patient.World Journal of Surgical Oncology 2007, 5:114 http://www.wjso.com/content/5/1/114
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the interdisciplinary tumorboard review a multifactorial
event was discussed with cetuximab possibly playing a
role. Other predisposing factors such as tracheal ischemia
after extended mediastinal lymphadenectomy and dam-
age of the membranous part after perforation of the stom-
ach with subsequent mediastinitis have certainly
contributed to the lethal outcome.
Since the reassessment of EGFR-expression in the gastric
and tracheal tissue was not possible one can only specu-
late about a possible contribution of cetuximab in addi-
tion to surgical complications after extensive
lymphadenectomy.
Yanaka et al., described the important role of EGF in resti-
tution of gastric mucosae in guinea pigs, that was signifi-
cantly inhibited by an anti-EGFR antibody [14].
Tarnawski  et al., demonstrated that EGF inhibits acid
secretion, exerts a trophic effect on gastroduodenal
mucosa, protects gastric mucosa against injury, mediates
mucosal adaptation and accelerates gastroduodenal ulcer
healing by stimulating cell migration and proliferation
[15]. Regarding the antivascular endothelial growth factor
antibody bevacicumab, several patients with severe bowel
complications such as bowel perforation have been
described [16] and several tracheo-esophageal fistula have
been reported which prompted a warning from the man-
ufacturer. No data exist with regard to neoadjuvant cetux-
imab therapy, where only small aphthous ulcers of the
oral mucosa have been reported to date [17].
Considering the bronchial system Barrow et al., hypothe-
sised that EGFR ligands and other growth factors mediate
bronchial epithelial repair in sheep [18]. White et al.,
demonstrated in human airway epithelial cells that EGF
induced epithelial repair via cell migration after mechan-
ical injury [19]. Puddicombe et al., showed that EGF-pro-
moted wound closure in airway epithelial cells was
retarded by a selective EGFR tyrosine kinase inhibitor (AG
1478) [20]. These preclinical data and the fact that despite
of a surgical complication we have never observed such a
combination of drain erosion of the complete stomach
wall and a non-manageable progressive tracheal defect
rise the question if a correlation between the neoadjuvant
cetuximab therapy in our patient and impaired EGFR-
mediated repair mechanisms in gastric and airway epithe-
lial cells exists. Unfortunately we could neither prove a
causal influence of cetuximab on the outcome nor defi-
nitely exclude a sole surgical complication, therefore we
tried to calculate the possibility of an adverse drug reac-
tion as shown below. In a phase II study adding cetuxi-
mab to neoadjuvant chemoradiotherapy in advanced
oesophageal cancer no such severe postoperative compli-
cations were observed in 15 operated patients although
early results suggested a lower complete response rate and
higher overall toxicity. One of the seventeen study
patients died after respiratory failure and sepsis, chemo-
therapy dose attenuation was required in 10 patients and
one patient was removed from the study due to prolonged
diarrhoea [11].
Assessment of the adverse drug reaction
Adverse drug reactions are suspected to be the 4th to 6th
leading cause of death in the US causing 106.000 fatalities
per year [21] although the meta-analayis has been heavily
criticized by others [22]. Cullen et al., have demonstrated
that voluntary reporting identifies only about 6% of ADRs
in the clinical routine and improvement is essential [23].
Linking these fatal complications after oesophagectomy
to an ADR after cetuximab is not that simple and this
remains the important limitation to this report. The com-
mon dermatologic reaction of acneiform eruption con-
fined to the face, scalp, chest and upper back areas
increased to a severe acute generalized exanthematic pus-
tulosis (figure 1), that was the reason to stop the neoadju-
vant treatment and continue with surgical treatment. We
tried to determine the probability of cetuximab causing
the events and to classify them as an ADR using systematic
criteria such as the algorithm of Naranjo and colleagues
that is commonly used [24]. The total score in the Naranjo
algorithm was two points, showing a "possible probabil-
ity". On the other hand five of the ten questions were not
applicable in our patient such as improvement of symp-
toms after medication discontinuation or reappearance
after readministration or placebo because the events were
delayed after neoadjuvant therapy and the outcome was
fatal. So the clinical usefulness of this algorithm was lim-
Autopsy results: inflammatory trachea (white arrow), tra- cheal leak in left main bronchus (black arrow), fibrinous pleu- risy (white triangle) Figure 3
Autopsy results: inflammatory trachea (white arrow), tra-
cheal leak in left main bronchus (black arrow), fibrinous pleu-
risy (white triangle).World Journal of Surgical Oncology 2007, 5:114 http://www.wjso.com/content/5/1/114
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ited and has been questioned before by other authors for
the use in critical ill ICU patients [25].
The role of cetuximab in ischemic damages of the stomach
and trachea after ooesophagectomy is unclear. While Bar-
tels et al., found tracheal complications in 4% after 785
esophagectomies (10.3% after radiochemotherapy but
none after chemotherapy alone) [13]. Kelley et al., found
no evidence that induction therapy adversely influences
the incidence of postoperative morbidity or mortality
after oesophagectomy in 155 patients [26].
Conclusion
Preclinical evidence exists for a possible correlation
between EGFR-antibody therapy and impaired EGFR-
mediated repair mechanisms in gastric and airway epithe-
lial cells. The widespread, in general safe and well-toler-
ated use of cetuximab in metastatic colorectal and locally
advanced squamous-cell head and neck cancer has to lead
to further investigations in neoadjuvant settings also in
other cancers such as esophageal cancer. In our patient
with severe postoperative complications the etiology of
this complication is likely to have been multifactorial,
with cetuximab possibly playing a role. Although the sus-
pected increase of risk for complications after oesophagec-
tomy needs to be confirmed in prospective trials before
final conclusions can be made, clinicians should be aware
of the possibility of these side effects. Careful recording of
all complications is necessary in ongoing and planned
studies to obtain more evidence about safety and toler-
ance of targeted therapies since these new biologic agents
may be not as safe as we have initially assumed.
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